A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. (Q47115446)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2018

Language	Label	Description	Also known as
English	A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study.	scientific article published in January 2018

Statements

scholarly article

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. (English)

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

chemoradiotherapy

0 references

author name string

Dong-Fang Meng

1

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Rui Sun

2

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Li-Xia Peng

3

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

You-Sheng Huang

4

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Qin Yang

5

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Dong-Hua Luo

6

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Wei-Han Hu

7

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Fang-Yun Xie

8

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Wei Luo

9

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Chong Zhao

10

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Ling Guo

11

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Hai-Qiang Mai

12

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Ming-Yuan Chen

13

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Ping Xie

14

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Li-Sheng Zheng

15

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Jun-Ping Yang

16

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Yan Mei

17

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Yuan-Yuan Qiang

18

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Liang Xu

19

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Chang-Zhi Li

20

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Bi-Jun Huang

21

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Chao-Nan Qian

22

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Rui Sun

23

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

publication date

1 January 2018

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Journal of Cancer

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

9

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

92-99

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

1

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

CDC42-interacting protein 4 promotes metastasis of nasopharyngeal carcinoma by mediating invadopodia formation and activating EGFR signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma : Survival outcome in a Korean multi-institutional retrospective study (KROG 11-06).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Analysis of decision making at a multidisciplinary head and neck tumor board incorporating evidence-based National Cancer Comprehensive Network (NCCN) guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Preliminary assessment of nasopharyngeal carcinoma incidence in the Philippines: a second look at published data from four centers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Treatment strategy and clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

23 May 2018

Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

15 August 2018

Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

15 August 2018

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

15 August 2018

Parotid gland-sparing 3-dimensional conformal radiotherapy results in less severe dry mouth in nasopharyngeal cancer patients: a dosimetric and clinical comparison with conventional radiotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

15 August 2018

Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

15 August 2018

A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5743715

15 August 2018

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099

1 reference

https://pubmed.ncbi.nlm.nih.gov/29290773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29290773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/29290773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma]

1 reference

https://pubmed.ncbi.nlm.nih.gov/29290773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In regards to Baujat et al.: Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients (Int J Radiat Oncol Biol Phys 2006;64:47-56)

1 reference

https://pubmed.ncbi.nlm.nih.gov/29290773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK

1 reference

https://pubmed.ncbi.nlm.nih.gov/29290773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors contributing to the efficacy of concurrent–adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/29290773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Grou

1 reference

https://pubmed.ncbi.nlm.nih.gov/29290773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29290773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.7150/JCA.21357

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5743715

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47115446&oldid=1477029339"